Clinical Trials on Hematopathology Eligible or CAR-t Cell Treatment
Total 294 results
-
The Lymphoma Academic Research OrganisationNovartis; Gilead SciencesRecruitingHematopathology Eligible or CAR-t Cell TreatmentFrance
-
Novartis PharmaceuticalsUniversity of PennsylvaniaRecruitingLong Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access ProgramUnited States, Japan, Australia, Germany, Spain, Belgium, Taiwan, Italy, Canada, Israel, Singapore, United Kingdom, Denmark, Finland, Norway, Austria, Netherlands, France
-
AmgenCompletedAny Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical TrialCanada, Spain, United States, Germany, Austria, France, Greece, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, South Africa, Switzerland, United Kingdom
-
Peking Union Medical College HospitalCSPC Ouyi Pharmaceutical Co., Ltd.RecruitingPeripheral T-cell Lymphoma | TreatmentChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.TerminatedPeripheral T Cell Lymphoma | Treatment-naïveChina
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRecruitingPatient Reported Outcome Measures | CAR T-Cell TherapySwitzerland
-
Hebei Senlang Biotechnology Inc., Ltd.Active, not recruitingSenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaChina
-
Hospices Civils de LyonNot yet recruitingDiffuse Large B-cell Lymphoma (DLBCL) | CAR-T Cells TreatmentFrance
-
Otsuka Pharmaceutical Co., Ltd.Active, not recruitingRelapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)Japan
-
Ningbo Cancer HospitalUnknownAdvanced Malignancies | PD-1 Antibody | CAR-T CellsChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UnknownRelapsed or Refractory Peripheral T-cell and NK/T-cell LymphomaChina
-
Samsung Medical CenterCompletedRelapsed and/or Refractory Cutaneous T-cell LymphomaKorea, Republic of
-
Sun Yat-sen UniversityRecruitingRelapsed or Refractory Peripheral T-cell LymphomaChina
-
Dizal PharmaceuticalsCompletedRelapsed or Refractory Peripheral T Cell LymphomaKorea, Republic of, United States, China, Australia
-
Shanghai International Medical CenterUnknownAdvanced Solid Tumor | PD-1 Antibody | CAR-T CellsChina
-
Zhejiang Genfleet Therapeutics Co., Ltd.RecruitingRelapsed or Refractory Peripheral T-cell Lymphoma (PTCL)China
-
Great Novel Therapeutics Biotech & Medicals CorporationRecruitingRelapsed or Refractory Peripheral T-cell LymphomaTaiwan
-
Kura Oncology, Inc.CompletedRelapsed or Refractory Peripheral T-Cell LymphomaUnited States, Spain, Korea, Republic of
-
Shanghai YingLi Pharmaceutical Co. Ltd.UnknownRelapsed or Refractory Peripheral T-Cell LymphomaChina
-
Samsung Medical CenterCompletedRelapsed or Refractory Peripheral T-cell LymphomaKorea, Republic of
-
Samsung Medical CenterRecruitingRelapsed and/or Refractory Non-Hodgkin T-cell LymphomaKorea, Republic of
-
Eisai Inc.Dr. Reddy's Laboratory; Citius PharmaceuticalsCompletedPersistent or Recurrent Cutaneous T-Cell LymphomaUnited States, Australia, Puerto Rico
-
Bristol-Myers SquibbRecruitingRelapsed or Refractory T-cell LymphomasJapan
-
Kura Oncology, Inc.AvailableHRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
-
Ono Pharmaceutical Co. LtdRecruitingRelapsed or Refractory T Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterUniversity of NebraskaCompletedT-cell Lymphomas | Relapsed or RefractoryUnited States
-
Affimed GmbHArtiva Biotherapeutics, Inc.RecruitingPeripheral T Cell Lymphoma | Relapsed or Refractory Hodgkin LymphomaUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Dren BioNovotechRecruitingAggressive NK Cell Leukemia | Hepatosplenic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Subcutaneous Panniculitis-Like T-Cell Lymphoma | Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | LGLL - Large Granular Lymphocytic Leukemia | Primary Cutaneous T-Cell Lymphoma - Category and other conditionsUnited States, Australia, France, Spain
-
Insel Gruppe AG, University Hospital BernRecruitingVaccine Immunity in CAR-T Cell Therapy RecipientsSwitzerland
-
Mundipharma K.K.CompletedRecurrent or Refractory PTCLJapan
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingCAR-T Cell | Ph Positive ALL | DasatinibChina
-
Dartmouth-Hitchcock Medical CenterCompletedLymphoma | Leukemia | Multiple Myeloma | Stem Cell Transplant | Hematopoietic Stem Cell Transplant | CAR T-Cell Therapy | HSCT | Cellular Therapy | CAR T-Cell TransplantUnited States
-
Mundipharma Research LimitedInnovative Therapies For Children with Cancer ConsortiumTerminatedRelapsed or Refractory T-cell Acute Lymphoblastic Leukaemia | B-cell Precursor Acute Lymphoblastic Leukaemia | T-cell Non-Hodgkin's LymphomaCzech Republic, Austria, France, Germany, Italy, United Kingdom
-
Institute of Hematology & Blood Diseases HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...UnknownNon-Hodgkin's Lymphoma | Peripheral T Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma | Chronic Lymphoblastic LeukemiaChina
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Recurrent Nasopharyngeal Undifferentiated Carcinoma | Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Stage IV Nasopharyngeal Undifferentiated Carcinoma...United States, Singapore, Japan, Hong Kong
-
Assistance Publique - Hôpitaux de ParisRecruitingInitial Radiological Diagnosis Eligible for Tumor Resection | Initial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type) | Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant TemozolomideBelgium, France, Switzerland
-
Massachusetts General HospitalActive, not recruitingHematologic Malignancy | CAR-T Cell TherapyUnited States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedPatients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment LinesItaly
-
Sidney Kimmel Cancer Center at Thomas Jefferson...American Society of Clinical OncologyCompletedBurkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Mantle Cell Lymphoma | Lymphoid Malignancies (New or Relapsed) | Adult T-cell Leukemia/LymphomaUnited States
-
Tel-Aviv Sourasky Medical CenterNovartisRecruitingB Cell Lymphoma | CART TreatmentIsrael
-
EutilexRecruitingEBV Associated Extranodal NK/T-cell Lymphoma | EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinomaKorea, Republic of
-
University of PittsburghRecruitingEczema | Mycosis Fungoides | Sezary Syndrome | Cutaneous T-cell Lymphoma | Atopic DermatitisUnited States
-
The Children's Hospital of Zhejiang University...Chongqing Precision Biotech Co., LtdRecruitingSystemic Lupus Erythematosus | CAR-T Cell TherapyChina
-
University of FreiburgCompletedCAR T-Cell-Related Encephalopathy Syndrome | ICANS, Grade UnspecifiedGermany
-
RenJi HospitalGracell Biotechnology Shanghai Co., Ltd.RecruitingCAR-T Cell TherapyChina
-
University of Illinois at ChicagoWithdrawnKidney Transplant Rejection | Positive FCXM (T or B Cell Positive) | Positive CDC Cross-Match (B Cell Positive) | Kidney/Pancreas Transplant RejectionUnited States
-
Mundipharma K.K.CompletedRecurrent or Refractory T/NK-cell MalignanciesJapan
-
Acrotech Biopharma Inc.CompletedB-cell Lymphoma | Hodgkin's Lymphoma | Relapsed or Refractory Lymphoproliferative Malignancies | Peripheral T-cell Lymphoma | Waldenstrom's MacroglobulinemiaUnited States